Acceleron Pharma Receivables

The latest receivables for XLRN is $34M as of September 2021. That compares with $23M in the prior-year period — up 51.6% year over year. Investors often review this figure alongside Acceleron Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, XLRN's receivables moved from $23M to $34M — a 51.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Acceleron Pharma's operating scale or balance-sheet position.

A receivables figure of $34M for XLRN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting XLRN's receivables ($34M), review year-over-year change from $23M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Acceleron Pharma's receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.